(4-hydroxy-6-methyl-2-thioxo-1,2-dihydroquinolin-3-yl)(4-nitrophenyl)methanone | 1190085-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (4-hydroxy-6-methyl-2-thioxo-1,2-dihydroquinolin-3-yl)(4-nitrophenyl)methanone
• 英文别名: (4-hydroxy-6-methyl-2-sulfanylidene-1H-quinolin-3-yl)-(4-nitrophenyl)methanone
• CAS: 1190085-06-3
• 化学式: C₁₇H₁₂N₂O₄S
• 分子量: 340.359
• InChiKey: UCIGNAFQPZAFJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] NEW CLASSES OF GABAa/BZR LIGANDS<br/>[FR] NOUVELLES CLASSES DE LIGANDS GABAA/BZR
  申请人：FORSKARPATENT I SYD AB

  公开号：WO2009123536A1

  公开（公告）日：2009-10-08

  The present invention relates to novel GABAA/BzR ligands of the general formulas (I), (II) and (III) wherein R1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms, and nitro, and R2 is selected from the group consisting of hydrogen, halogen and alkyl having 1 to 2 carbon atoms, as well as the use of these compounds for treating anxiolytic, anticonvulsant, sedative- hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals including pharmaceutical compositions comprising the same

  本发明涉及一种新型的GABAA/BzR配体，其一般式为(I)、(II)和(III)，其中R1从氢、卤素、具有1-2个碳原子的卤代烷基、在烷基链中具有1-3个碳原子的烷氧基、具有1-3个碳原子的烷基和硝基组成的群中选择，R2从氢、卤素和具有1-2个碳原子的烷基组成的群中选择，以及利用这些化合物治疗哺乳动物中的抗焦虑、抗惊厥、镇静催眠和肌松条件，以及包括这些化合物的药物组合物。
• NEW CLASSES OF GABAA/BZR LIGANDS
  申请人：Nielsen Mogens

  公开号：US20110105553A1

  公开（公告）日：2011-05-05

  The present invention relates to novel GABA A /BzR ligands of the general formulas (I), (II) and (III) wherein R 1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms, and nitro, and R 2 is selected from the group consisting of hydrogen, halogen and alkyl having 1 to 2 carbon atoms, as well as the use of these compounds for treating anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals including pharmaceutical compositions comprising the same

  本发明涉及一种新型GABAA/BzR配体，其通式为(I)、(II)和(III)，其中R1选自氢、卤素、具有1-2个碳原子的卤代烷基、具有1-3个碳原子的烷氧基、具有1-3个碳原子的烷基和硝基的群体，R2选自氢、卤素和具有1-2个碳原子的烷基的群体，以及使用这些化合物治疗哺乳动物的抗焦虑、抗惊厥、镇静催眠和肌松作用症状，以及包括这些化合物的制药组合物。
• US8481561B2
  申请人：——

  公开号：US8481561B2

  公开（公告）日：2013-07-09